XML 23 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Treasury Stock
Verily Life Sciences
Additional paid-in capital
Convertible Notes due 2022
Convertible Notes due 2022
Additional paid-in capital
Convertible Notes due 2023
Convertible Notes due 2023
Additional paid-in capital
Beginning Balance, Shares at Dec. 31, 2015   81.7                  
Beginning Balance at Dec. 31, 2015 $ 221.2 $ 0.1 $ 776.8 $ (0.3) $ (555.4) $ 0.0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock under equity incentive plans, Shares   2.7                  
Issuance of common stock under equity incentive plans 4.4   4.4                
Issuance of common stock for Employee Stock Purchase Plan, shares   0.1                  
Issuance of common stock for Employee Stock Purchase Plan 6.0   6.0                
Issuance of common stock in connection with acquisition, shares   0.1                  
Issuance of common stock in connection with acquisition 7.2           $ 7.2        
Share-based compensation expense 111.3   111.3                
Net loss (65.6)       (65.6)            
Other comprehensive income (0.7)     (0.7)              
Ending Balance, shares at Dec. 31, 2016   84.6                  
Ending Balance at Dec. 31, 2016 283.8 $ 0.1 905.7 (1.0) (621.0) 0.0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock under equity incentive plans, Shares   2.3                  
Issuance of common stock under equity incentive plans 2.7   2.7                
Issuance of common stock for Employee Stock Purchase Plan, shares   0.1                  
Issuance of common stock for Employee Stock Purchase Plan 7.4   7.4                
Share-based compensation expense 106.7   106.7                
Equity component of convertible note issuance, net of issuance costs               $ 70.6 $ 70.6    
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification | Accounting Standards Update 2016-09     0.6   (0.6)            
Net loss (50.2)       (50.2)            
Other comprehensive income (1.6)     (1.6)              
Ending Balance, shares at Dec. 31, 2017   87.0                  
Ending Balance at Dec. 31, 2017 419.4 $ 0.1 1,093.7 (2.6) (671.8) 0.0          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of common stock under equity incentive plans, Shares   1.8                  
Issuance of common stock under equity incentive plans 1.9   1.9                
Issuance of common stock for Employee Stock Purchase Plan, shares   0.2                  
Issuance of common stock for Employee Stock Purchase Plan 8.9   8.9                
Share-based compensation expense 101.9   101.9                
Equity component of convertible note issuance, net of issuance costs (218.9)   (218.9)             $ 171.6 $ 171.6
Issuance of common stock for collaborative research and development fees, shares   1.8                  
Stock Issued During Period, Value, Purchase of Assets 217.7   217.7                
Sale of warrants $ 183.8   183.8                
Purchases of treasury stock, shares (0.8) (0.8)                  
Purchases of treasury stock $ (100.0)         (100.0)          
Net loss (127.1)                    
Other comprehensive income 4.1                    
Ending Balance, shares at Dec. 31, 2018   90.0                  
Ending Balance at Dec. 31, 2018 $ 663.3 $ 0.1 $ 1,560.6 $ 1.5 $ (798.9) $ (100.0)